HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Desialylation of airway epithelial cells during influenza virus infection enhances pneumococcal adhesion via galectin binding.

Abstract
The continued threat of worldwide influenza pandemics, together with the yearly emergence of antigenically drifted influenza A virus (IAV) strains, underscore the urgent need to elucidate not only the mechanisms of influenza virulence, but also those mechanisms that predispose influenza patients to increased susceptibility to subsequent infection with Streptococcus pneumoniae. Glycans displayed on the surface of epithelia that are exposed to the external environment play important roles in microbial recognition, adhesion, and invasion. It is well established that the IAV hemagglutinin and pneumococcal adhesins enable their attachment to the host epithelia. Reciprocally, the recognition of microbial glycans by host carbohydrate-binding proteins (lectins) can initiate innate immune responses, but their relevance in influenza or pneumococcal infections is poorly understood. Galectins are evolutionarily conserved lectins characterized by affinity for β-galactosides and a unique sequence motif, with critical regulatory roles in development and immune homeostasis. In this study, we examined the possibility that galectins expressed in the airway epithelial cells might play a significant role in viral or pneumococcal adhesion to airway epithelial cells. Our results in a mouse model for influenza and pneumococcal infection revealed that the murine lung expresses a diverse galectin repertoire, from which selected galectins, including galectin 1 (Gal1) and galectin 3 (Gal3), are released to the bronchoalveolar space. Further, the results showed that influenza and subsequent S. pneumoniae infections significantly alter the glycosylation patterns of the airway epithelial surface and modulate galectin expression. In vitro studies on the human airway epithelial cell line A549 were consistent with the observations made in the mouse model, and further revealed that both Gal1 and Gal3 bind strongly to IAV and S. pneumoniae, and that exposure of the cells to viral neuraminidase or influenza infection increased galectin-mediated S. pneumoniae adhesion to the cell surface. Our results suggest that upon influenza infection, pneumococcal adhesion to the airway epithelial surface is enhanced by an interplay among the host galectins and viral and pneumococcal neuraminidases. The observed enhancement of pneumococcal adhesion may be a contributing factor to the observed hypersusceptibility to pneumonia of influenza patients.
AuthorsMihai Nita-Lazar, Aditi Banerjee, Chiguang Feng, Mohammed N Amin, Matthew B Frieman, Wilbur H Chen, Alan S Cross, Lai-Xi Wang, Gerardo R Vasta
JournalMolecular immunology (Mol Immunol) Vol. 65 Issue 1 Pg. 1-16 (May 2015) ISSN: 1872-9142 [Electronic] England
PMID25597246 (Publication Type: Journal Article, Research Support, N.I.H., Extramural, Research Support, U.S. Gov't, Non-P.H.S.)
CopyrightCopyright © 2014 Elsevier Ltd. All rights reserved.
Chemical References
  • Adhesins, Bacterial
  • Galectin 1
  • Galectin 3
  • Hemagglutinin Glycoproteins, Influenza Virus
  • Neuraminidase
Topics
  • Adhesins, Bacterial
  • Animals
  • Apoptosis
  • Bacterial Adhesion (physiology)
  • Cell Line
  • Disease Susceptibility
  • Epithelial Cells (metabolism)
  • Galectin 1 (biosynthesis, metabolism)
  • Galectin 3 (biosynthesis, metabolism)
  • Hemagglutinin Glycoproteins, Influenza Virus
  • Humans
  • Influenza A virus (pathogenicity)
  • Mice
  • Mice, Inbred C57BL
  • Neuraminidase (pharmacology)
  • Orthomyxoviridae Infections (pathology)
  • Pneumococcal Infections (pathology)
  • Protein Binding (drug effects)
  • Respiratory Mucosa (cytology, microbiology, virology)
  • Streptococcus pneumoniae (pathogenicity)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: